# Primary Immunodeficiency Diseases Market and Forecast 2025-2033

Limited-Time Offer \[Flat 15% Discount\] [Dismiss](#)

[Skip to content](#content "Skip to content")

[Updated Data Matrix Available](https://www.ihealthcareanalyst.com/research-services/)

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

[Home](https://www.ihealthcareanalyst.com/) » [Reports](https://www.ihealthcareanalyst.com/shop/) » [Pharmaceuticals](https://www.ihealthcareanalyst.com/reports/pharmaceuticals/)

![Awaiting product image](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)

![Awaiting product image](https://www.ihealthcareanalyst.com/wp-content/uploads/2019/08/report-icon4-e1565791186498.png)

# Primary Immunodeficiency Diseases Market by Disease (Antibody Deficiency – Agammaglobulinaemia, Common Variable Immune Deficiency, IgG Subclass Deficiency, SIgAD; Cellular Immunodeficiency – Ataxia Telangiectasia, DiGeorge Syndrome, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome; Innate Immune Disorders – Complement Deficiencies, and Hyper IgE Syndrome) and Test Types (Blood and Prenatal Testing), and Treatment Types (Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem Cell and Gene Therapy) and Forecast 2025-2033

$3,000.00

## Report Specifications: Market Size, Market Share, Growth Trends, Forecast, Geography

Primary immunodeficiency diseases or disorders (PIDD or PI) are caused as part of the body’s immune system is missing or does not function normally, such that it is an inherited flaw in the immune system that increases the susceptibility to infections. Besides susceptibility to infections, PIDD may cause other health problems as well, including allergies, asthma, swollen joints, digestive tract problems, growth problems or an enlarged liver and spleen.

The global primary immunodeficiency disease market is dominated by North America and Europe, collectively accounting for major share of the market in 2015. National PID registries worldwide, increasing healthcare expenditure and government support are the major factors driving the global primary immunodeficiency diseases market during the forecast period.

The global primary immunodeficiency diseases market report estimates the market size ($million 2023 to 2033), market share, growth trends, and forecast (CAGR% 2025 to 2033).

The global primary immunodeficiency diseases market segmented by disease (antibody deficiency – Agammaglobulinaemia, common variable immune deficiency, IgG subclass deficiency, SIgAD; cellular immunodeficiency – Ataxia Telangiectasia, DiGeorge syndrome, Hyper IgM syndromes, Wiskott-Aldrich syndrome; innate immune disorders – Complement deficiencies, and Hyper IgE syndrome), by test type (blood and prenatal testing), and by treatment modality (immunoglobulin replacement therapy, antibiotics therapy, stem cell and gene therapy), and geography.

The global primary immunodeficiency diseases market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

The global primary immunodeficiency diseases market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.

Major players operating in the global primary immunodeficiency diseases market and included in this report are Baxter International, Inc., Bio Products Laboratory, Biotest AG, CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB S.A., and Octapharma AG.

**Salient Features of the report:**  
1\. Bottom-up research methodology (assumptions) for market size estimation and forecast.  
2\. Global Number of patient population for PID (subtypes), by country  
3\. Global Number of patient population for treatment or therapy, by country  
4\. Global Number of PID Patients, by 15 Most Commonly Identified PID  
5\. PID Patient’s Gender and Age – Global Comparative Analysis

**DATA INCLUDED:** Primary Immunodeficiency Diseases Market Size, Primary Immunodeficiency Diseases Market Share, Primary Immunodeficiency Diseases Market Growth Rates, Primary Immunodeficiency Diseases Market Trends, and Primary Immunodeficiency Diseases Market Forecast to 2033

**Market Data:**

*   Estimation Base Year: 2024
*   Historical Data Range: 2023-2024
*   Forecast Period: 2025-2033
*   Market Representation: Revenue in $million and CAGR % from 2025 to 2033
*   Regional Scope: North America, Europe, Asia Pacific, Latin America, Rest of the World (Middle East & Africa)
*   Country Scope: U.S., Canada, U.K., Germany, France, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, South Africa, South Korea, Saudi Arabia, UAE, and other countries.
*   Report Coverage: Revenue forecasts, company market share, competitive landscape analysis, growth factors, and market trends
*   Customization Scope (15% Free): Accommodation of specific or custom requirements beyond the current report scope.

**Qualitative Analysis:**

*   Industry Overview
*   Industry Trends
*   Market Driver, Restraints, and Opportunities
*   Market Size
*   Growth Trends
*   Porter’s Five Forces Analysis
*   Market Attractiveness Matrix
*   Competitive Landscape
    *   Company Overview
    *   Financial Performance
    *   Product Portfolio
    *   Strategic Insights
    *   Recent Developments

**Quantitative Analysis:**

*   Market Size Projections: Comprehensive estimates and forecasts for all segments
*   Regional Market Analysis: Estimates and forecasts for key countries
*   Corporate Financial Performance: Analysis of company financials
*   Competitive Landscape: Market share analysis of leading companies

Choose License Type

Choose an optionSingle-user LicenseMulti-user LicenseCorporate License[Clear](#)

Primary Immunodeficiency Diseases Market by Disease (Antibody Deficiency – Agammaglobulinaemia, Common Variable Immune Deficiency, IgG Subclass Deficiency, SIgAD; Cellular Immunodeficiency - Ataxia Telangiectasia, DiGeorge Syndrome, Hyper IgM Syndromes, Wiskott-Aldrich Syndrome; Innate Immune Disorders - Complement Deficiencies, and Hyper IgE Syndrome) and Test Types (Blood and Prenatal Testing), and Treatment Types (Immunoglobulin Replacement Therapy, Antibiotics Therapy, Stem Cell and Gene Therapy) and Forecast 2025-2033 quantity 

Buy Report   

For inquiries regarding discounts on single or bundled report purchases, please reach out to us.

*   [Table of Contents PH](#tab-table-of-contents-ph)
*   [Market Segments and Companies](#tab-market-segments-and-companies)
*   [Request ToC / Sample](#tab-request-toc-sample-discount)

1.  **Introduction**
2.  **Executive Summary**
    *   Market Size Estimation ($million, 2023-2033)
    *   Forecast Estimation ($million and CAGR%, 2025-2033)
3.  [**Research Methodology**](https://www.ihealthcareanalyst.com/research-methodology/)
4.  **Market Landscape**
    *   Market Dynamics
        *   Drivers
        *   Barriers
        *   Opportunities
    *   Market Share Analysis
        *   Companies
        *   Drugs
    *   Market Trends Analysis
        *   Key success factors
        *   Market Growth Rate
    *   Market Attractiveness Analysis
    *   Market Profitability Analysis
        *   Buyer power
        *   Supplier power
        *   Barriers to entry
        *   Threat of substitute products
        *   Rivalry among firms in the industry
    *   Distribution Channels
5.  **Market Segmentation** \[_refer Market Segments and Companies Tab_\]
    *   Drug Class or Drug (Brand) Type
    *   Drug or Disorder Test
    *   Indication Type
    *   Drug Treatment
    *   Mechanism of Action
    *   Therapeutic Area or Nature of Application
    *   End User Groups
6.  **Geography (Region, Country)**
    *   North America (U.S., Canada)
    *   Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    *   Asia Pacific (Japan, China, India, Rest of APAC)
    *   Latin America (Brazil, Mexico, Rest of LA)
    *   Rest of the World (Middle East & Africa)
7.  **Regulatory Overview** 
    *   IND, NDA filed, FDA, EMEA Approvals
8.  **Pipeline Analysis** (Phase 1, 2 and 3 Drugs)
    *   Phase 3 Drugs Forecast Estimation (Approval to 2033)
    *   Phase 1 and 2 Drugs – Qualitative Analysis
9.  **Company Profiles** \[_refer Market Segments and Companies Tab_\]
    *   Company Overview
    *   Financial Snapshot
    *   Product Portfolio
    *   Business Strategies
    *   Recent Developments
10.  **Recommendations**
11.  **References**

**Key Questions Answered:**  
1\. What are the factors driving and limiting this market, key success factors and challenges?  
2\. Which are the leading competitors in the market, their market share, profitability and key trends by product, technology, services portfolio?  
3\. How do markets perform between countries and regions?  
4\. What market segments are contributing to maximum share and greatest growth?  
5\. What is the product or procedure volumes by country and regions?

**Actionable Insights Included:**  
1\. Product portfolio matrix (Share vs. Growth)  
2\. Market attractiveness (Region vs. Growth)  
3\. Spot matrix (Product vs. Region)  
4\. Geographic distribution matrix (Share vs. Growth)

**Primary Immunodeficiency Diseases Market**

1\. **Disease Type**  
1.1. Antibody Deficiency  
1.1.1. Agammaglobulinaemia  
1.1.2. Common Variable Immune Deficiency  
1.1.3. IgG Subclass Deficiency  
1.1.4. Selective IgA Deficiency (SIgAD)  
1.1.5. Others  
1.2. Cellular Immunodeficiency  
1.2.1. Ataxia Telangiectasia  
1.2.2. DiGeorge Syndrome  
1.2.3. Hyper IgM Syndromes  
1.2.4. Wiskott-Aldrich Syndrome  
1.2.5. Others  
1.3. Innate Immune Disorder  
1.3.1. Complement Deficiencies  
1.3.2. Hyper IgE Syndrome  
1.3.3. Others

2\. **Test Type**  
2.1. Blood Testing  
2.2. Prenatal Testing

3\. **Treatment Type**  
3.1. Immunoglobulin Replacement Therapy  
3.2. Antibiotics Therapy  
3.3. Stem cell and Gene Therapy  
3.4. Others

4\. **Company Profiles**  
4.1. Baxter International, Inc.  
4.2. Bio Products Laboratory  
4.3. Biotest AG  
4.4. CSL Behring LLC  
4.5. Grifols S.A.  
4.6. Kedrion S.p.A.  
4.7. LFB S.A.  
4.8. Octapharma AG

Salient features of the report:

1\. Bottom-up research methodology (assumptions) for market size estimation and forecast.  
2\. Global Number of patient population for PID (sub types), by country  
3\. Global Number of patient population for treatment or therapy, by country  
4\. Global Number of PID Patients, by 15 Most Commonly Identified PIDs  
5\. PID Patient’s Gender and Age – Global Comparative Analysis

**Request Table of Contents / Sample Report**

Full Name\*

Company Email\*

Phone Number\* \[Please add country code\]

Subject\*

Message\*

Resource Links

*   [About Us](https://www.ihealthcareanalyst.com/about/)
*   [Clinical Trials](https://www.ihealthcareanalyst.com/clinical-trials-dashboard/)
*   [Drugs@FDA](https://www.ihealthcareanalyst.com/drugs-fda-dashboard/)
*   [Orange Book](https://www.ihealthcareanalyst.com/orange-book-dashboard/)
*   [Premarket Approval](https://www.ihealthcareanalyst.com/premarket-approval-pma/)
*   [Premarket Notification](https://www.ihealthcareanalyst.com/premarket-notification-510k/)
*   [Publications](https://www.ihealthcareanalyst.com/publications/)

Terms and Conditions

*   [FAQs](https://www.ihealthcareanalyst.com/faqs/)
*   [Careers](https://www.ihealthcareanalyst.com/careers/)
*   [Terms of Use](https://www.ihealthcareanalyst.com/terms/)
*   [How to Order](https://www.ihealthcareanalyst.com/order/)
*   [Return Policy](https://www.ihealthcareanalyst.com/return/)
*   [Privacy Policy](https://www.ihealthcareanalyst.com/privacy/)
*   [Disclaimer Policy](https://www.ihealthcareanalyst.com/disclaimer/)

Secure Online Payment

![iHealthcareAnalyst, Inc.](https://www.ihealthcareanalyst.com/wp-content/uploads/2018/07/creditcard-payment-logos-300x48.jpg)

Search

Search

Contact Address

**US Office:** 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States  
Phone: +1 (314) 315-4764  
**India Office:** 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India  
Phone: +91 (20) 25898524  
Email: [\[email protected\]](/cdn-cgi/l/email-protection#3e4d5f525b4d7e57565b5f524a565d5f4c5b5f505f52474d4a105d5153)

[](# "Scroll back to top")

Search for: